Skip to main navigation Skip to search Skip to main content

Where are we moving in the classification of idiopathic inflammatory myopathies?

  • National Institute of Neuroscience, Kodaira
  • National Center of Neurology and Psychiatry
  • Charité-University Medicine Berlin

Research output: Contribution to journal › Review article › peer-review

107 Citations (Scopus)

Abstract

Purpose of reviewDiscoveries of myositis-specific antibodies, transcriptomic signatures, and clinicoseropathological correlation support classification of idiopathic inflammatory myopathies (IIM) into four major subgroups: dermatomyositis, immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (ASS), and inclusion body myositis (IBM) whereas leaving polymyositis as a historical nonspecific diagnosis of exclusion. This review summarizes and comments on recent knowledge regarding the major subgroup of IIM.Recent findingsType 1 interferon (IFN1) pathway activation is the most prominent in dermatomyositis whereas type 2 interferon (IFN2) pathway activation is high in IBM and ASS; neither pathway is distinct in IMNM. Myxovirus-resistant protein A, IFN1 surrogate marker, is now one of definite dermatomyositis muscle biopsy criteria in the new 2018 European Neuromuscular Centre classification of dermatomyositis; the classification emphasizes on different categorization with and without dermatomyositis-specific antibody result. Novel HLA loci associated with anti-TIF1-γ, anti-Mi-2, and anti-Jo-1 antibodies in Caucasian population are identified. Associations of chaperon-assisted selective autophagy (CASA) and complement-mediated autoimmunity in IMNM as well as highly differentiated T cells in IBM are discovered.SummaryCurrent IIM classification requires integrated clinicoseropathological approaches. Additional information, such as transcriptomics, HLA haplotyping, and potential biomarkers help tailoring categorization that may have future diagnostic and therapeutic implications.

Original languageEnglish
Pages (from-to)590-603
Number of pages14
JournalCurrent Opinion in Neurology
Volume33
Issue number5
DOIs
Publication statusPublished - 1 Oct 2020
Externally publishedYes

Keywords

  • antisynthetase syndrome
  • dermatomyositis
  • immune checkpoint inhibitor
  • immune-mediated necrotizing myopathy
  • inclusion body myositis
  • myositis-specific antibody

Fingerprint

Dive into the research topics of 'Where are we moving in the classification of idiopathic inflammatory myopathies?'. Together they form a unique fingerprint.

Cite this